Theravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the TheraVance BioPharma third quarter 2024 conference call. During the presentation, all participants will be in a listen-only mode. A question and answer session will follow the company's formal remarks. To ask a question, press the star key followed by the digit 1, digit 1 on your phone. Again, that's star 1, 1 to ask a question. If listening via webcast, please mute your audio on your webcast device before asking a question. over the phone. I'll repeat the instructions after management completes their prepared remarks. Also, today's conference call is being recorded. And now I'd like to turn the conference over to Rick Whittingham, Chief Executive Officer. Please go ahead, sir. Good afternoon, and welcome to Theravance Myocardia's third quarter 2024 earnings results conference call. I encourage you to review our forward-looking statements disclaimer on slide two, which covers certain risk factors which could cause actual results to differ materially from any forward-looking statements that we might make in today's call, and which are described further in our filings with the SEC. You will find today's agenda on slide three, along with members of the TheraVance leadership team who will join me in the call today. These are Rhonda Farnham, Chief Business Officer, Aziz Swaf, Chief Financial Officer, and Anya Miller, Head of Development. Now, if you turn to slide four, I'd like to cover our most recent operational and financial results. Starting on the left, we're pleased to have delivered sequentially improved Upelry quarterly net sales performance in partnership with Beatrice, having driven 7% growth year on year and 14% quarter on quarter to 62.2 million and a new launch today high. Third quarter...